New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Where the cash went Fiscal 2026, year to Jun 30, 2026

Free cash flow was −$35.8M: capital expenditures were more than operating cash flow. Cash fell by $17.0M. What is a cash flow statement?

Free cash flow
−$35.8M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$17.0M over the period
Where the cash went, in millions of dollars
Operating cash flow−35.8
Free cash flow−35.8
Shares issued, net+24.0
Other−5.1
Change in cash−17.0

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Jun '26 Jun '25 Jun '24
Net Income
(38.65) (24.83) (31.44)
Operating Cash Flow
(35.82) (23.73) (15.07)
Investing cash flow
(3.68) 1.15 —
Financing cash flow
22.65 29.42 19.59
Ending Cash
2.81 18.86 12.18
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026